Table 3. Analyses of survival outcome by clinicopathologic characteristics, treatment type, and expression of hormone receptors (n=42).
| Variables | Univariate | Multivariate | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|---|---|
| DFS (%) | p | OR | p | OS (%) | p | OR | p | ||
| Clinicopathologic characteristics | |||||||||
| Age (<47 vs. ≥47) | 47.6 vs. 42.9 | 0.198 | 76.2 vs. 57.1 | 0.094 | |||||
| Parity (≤2 vs. >2) | 77.8 vs. 36.4 | 0.057 | 88.9 vs. 60.6 | 0.127 | |||||
| Menopause (no vs. yes) | 48.1 vs. 40.0 | 0.050 | 77.8 vs. 46.7 | 0.005 | 1.7 (0.5–5.5) | 0.366 | |||
| BMI (<23 vs. ≥23) | 31.6 vs. 56.5 | 0.253 | 68.4 vs. 65.2 | 0.777 | |||||
| Tumor size (<10 vs. ≥10) | 59.3 vs. 20.0 | 0.013 | 0.6 (0.2–2.4) | 0.471 | 81.5 vs. 40.0 | 0.005 | 0.8 (0.2–3.8) | 0.745 | |
| Mitotic count (≤10 vs. >10) | 69.2 vs. 28.6 | 0.042 | 1.1 (0.3–4.7) | 0.888 | 76.9 vs. 71.4 | 0.815 | |||
| FIGO stage (I, II vs. III, IV) | 60.0 vs. 8.3 | <0.001 | 5.8 (1.2–28.4) | 0.029 | 86.7 vs. 16.7 | <0.001 | 12.0 (2.5–56.6) | 0.002 | |
| Ovarian preservation (no vs. yes) | 44.4 vs. 46.7 | 0.509 | 66.7 vs. 66.7 | 0.794 | |||||
| Lymphadenectomy (no vs. yes) | 52.2 vs. 36.8 | 0.049 | 1.7 (0.6–5.3) | 0.333 | 73.9 vs. 57.9 | 0.143 | |||
| Adjuvant therapy (no vs. yes) | 60.0 vs. 37.0 | 0.349 | 66.7 vs. 66.7 | 0.746 | |||||
| Hormone receptors | |||||||||
| ERα (0 vs. 1+, 2+, 3+) | 50.0 vs. 38.9 | 0.961 | 54.2 vs. 83.3 | 0.054 | |||||
| ERβ (2+ vs. 3+) | 57.1 vs. 42.9 | 0.191 | 71.4 vs. 65.7 | 0.614 | |||||
| PR (0 vs. 1+, 2+, 3+) | 36.4 vs. 55.0 | 0.043 | 1.1 (0.3–3.7) | 0.853 | 54.5 vs. 80.0 | 0.039 | 0.4 (0.1–1.8) | 0.250 | |
| AR (0 vs. 1+, 2+, 3+) | 35.5 vs. 72.7 | 0.023 | 0.2 (0.0–0.9) | 0.032 | 54.8 vs. 100.0 | 0.014 | 0 (0.0–2.9) | 0.968 | |
| GnRH (3+) | 45.2 | - | 66.7 | - | |||||
| CYP19A1 (2+ vs. 3+) | 71.4 vs. 40.0 | 0.035 | 7.5 (0.7–81.9) | 0.098 | 85.7 vs. 62.9 | 0.179 | |||
AR, androgen receptor; BMI, body mass index; CYP19A1, cytochrome P450, family 19, subfamily A, polypeptide 1; DFS, disease-free survival; ER, estrogen receptor; FIGO, International Federation of Gynecology and Obstetrics; GnRH, gonadotropin releasing hormone; OR, odds ratio; OS, overall survival; PR, progesterone receptor.